文献速递骨质疏松与代谢性骨病创伤骨科

抗骨质疏松药物暴露时间与首次髋部骨折风险:挪威骨质疏松流行病学研究(NOREPOS)的人群wide研究

Time-varying exposure to anti-osteoporosis drugs and risk of first-time hip fracture: a population wide study within the Norwegian Epidemiologic Osteoporosis Studies (NOREPOS).
PubMed 文献 · Osteoporos Int · 2023-04-27

在挪威2005-2016年50-89岁女性中,使用双膦酸盐和地舒单抗与首次髋部骨折风险降低相关,完全校正后HR分别为0.95(95%CI 0.91-0.99)和0.60(95%CI 0.47-0.76);曾用双膦酸盐的地舒单抗使用者风险最低(HR 0.42,95%CI 0.29-0.61)。

要点

  • 双膦酸盐使用与髋部骨折风险降低相关(HR 0.95,95%CI 0.91-0.99)。
  • 地舒单抗使用与髋部骨折风险降低相关(HR 0.60,95%CI 0.47-0.76)。
  • 曾用双膦酸盐的地舒单抗使用者风险最低(HR 0.42,95%CI 0.29-0.61)。

核心结论

  • 在人群wide真实世界数据中,校正合并症后,暴露于双膦酸盐和地舒单抗的女性髋部骨折风险低于未暴露人群。
  • 治疗时长和治疗史影响骨折风险。
  • 治疗高风险个体可能预防未来髋部骨折。

研究设计与样本

  • 基于挪威骨质疏松流行病学研究(NOREPOS)的人群wide研究,纳入2005-2016年挪威50-89岁女性。
  • 挪威处方数据库(NorPD)提供双膦酸盐、地舒单抗及其他药物暴露数据以计算Rx-Risk合并症指数。
  • 采用灵活参数生存分析,以年龄为时间尺度,双膦酸盐和地舒单抗暴露为时变变量。
  • 随访至髋部骨折或删失(死亡、移民、90岁)或2016年12月31日,以先发生者为准。

主要发现

  • 1,044,661名女性中,77,755名(7.2%)曾暴露于双膦酸盐,4,483名(0.4%)曾暴露于地舒单抗。
  • 完全校正后髋部骨折风险:双膦酸盐使用HR 0.95(95%CI 0.91-0.99),地舒单抗使用HR 0.60(95%CI 0.47-0.76)。
  • 与人群相比,双膦酸盐治疗3年后髋部骨折风险显著降低,地舒单抗治疗6个月后显著降低。
  • 曾用双膦酸盐的地舒单抗使用者骨折风险最低:与未暴露人群相比HR 0.42(95%CI 0.29-0.61)。

临床怎么用

  • 原文结论指出,治疗高风险个体可能预防未来髋部骨折。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: We investigated the association between bisphosphonate and denosumab use and risk of hip fracture in Norway. These drugs protect against fractures in clinical trials, but their population-level effect is unknown. Our results showed lowered risk of hip fracture for treated women. Treatment of high-risk individuals could prevent future hip fractures. PURPOSE: To investigate whether bisphosphonates and denosumab reduced the risk of first-time hip fracture in Norwegian women when adjusting for a medication-based comorbidity index. METHODS: Norwegian women aged 50-89 in 2005-2016 were included. The Norwegian prescription database (NorPD) supplied data on exposures to bisphosphonates, denosumab, and other drugs for the calculation of the Rx-Risk Comorbidity Index. Information on all hip fractures treated in hospitals in Norway was available. Flexible parametric survival analysis was used with age as time scale and with time-varying exposure to bisphosphonates and denosumab. Individuals were followed until hip fracture or censoring (death, emigration, age 90 years), or 31 December 2016, whichever occurred first. Rx-Risk score was included as a time-varying covariate. Other covariates were marital status, education, and time-varying use of bisphosphonates or denosumab with other indications than osteoporosis. RESULTS: Of 1,044,661 women 77,755 (7.2%) were ever-exposed to bisphosphonate and 4483 (0.4%) to denosumab. The fully adjusted hazard ratios (HR) were 0.95 (95% confidence interval (CI): 0.91-0.99) for bisphosphonate use and 0.60 (95% CI: 0.47-0.76) for denosumab use. Bisphosphonate treatment gave a significantly reduced risk of hip fracture compared with the population after 3 years and denosumab after 6 months. Fracture risk was lowest in denosumab users who had previously used bisphosphonate: HR 0.42 (95% CI: 0.29-0.61) compared with the unexposed population. CONCLUSIONS: In population-wide real-world data, women exposed to bisphosphonates and denosumab had a lower hip fracture risk than the unexposed population after adjusting for comorbidity. Treatment duration and treatment history impacted fracture risk.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Riska BSL, Gunnes N, Stigum H, et al. Time-varying exposure to anti-osteoporosis drugs and risk of first-time hip fracture: a population wide study within the Norwegian Epidemiologic Osteoporosis Studies (NOREPOS). Osteoporos Int. 2023. PMID: 37100950. doi:10.1007/s00198-023-06752-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。